These icons indicate there is something to be interacted with. Click it when you see it.
Which pump system do you commonly use for routine phacoemulsification?
These icons indicate there is something to be interacted with. Click it when you see it.
How confident are you in selecting the optimal OVD to manage intraoperative issues?
These icons indicate there is something to be interacted with. Click it when you see it.
Which phaco technology advancement has impacted your practice the most?
In this interview, Dr Ahmed answers the following questions:
Dr Ike K Ahmed is the John R & Hazel M Robertson presidential endowed chair and professor at the Department of Ophthalmology Visual Sciences at the University of Utah, USA. He is also the director of the Alan S Crandall Center for Glaucoma Innovation at the John A Moran Eye Center, and the director of the Glaucoma & Advanced Anterior Segment Surgery (GAASS) Fellowship at the University of Toronto, Canada, and chief innovation officer at Prism Eye Institute, Canada. Dr Ahmed is a surgeon scientist who has been an international leader in novel approaches in glaucoma, complex cataract and lens implant surgery, practising and conducting research in both Canada and the USA. He is recognized as being one of the most experienced complex eye surgeons globally, and patients are referred to him from around the world. His leadership and pioneering work in innovative glaucoma surgery includes developing and coining the terms ‘interventional glaucoma (IG)’, ‘microinvasive glaucoma surgery (MIGS)’ and ‘microinvasive bleb surgery (MIBS)’. Dr Ahmed’s lab at the Crandall Center is focused on glaucoma surgical devices and laser therapies and Dr Ahmed has published widely. Dr Ahmed received the Binkhorst Medal, which is awarded to the world’s most prominent ophthalmologists whose careers have made significant impact on the science and practice of ophthalmology, and he was recognized as #1 Most Influential Ophthalmologist in the World by The Ophthalmologist. Recently, he was bestowed with the King Charles III Coronation Medal for his extraordinary contributions to the field.
Dr Ike K Ahmed discloses: Consultancy fees from AbbVie, Ace Vision Group Inc, Alcon, Aliph Medical, Apellis Pharmaceuticals, Aquea Health Inc, ArcScan, Avellino Lab USA Inc, Avisi Technologies Inc, Balance Ophthalmics, Bausch and Lomb, Beaver Visitec, Belkin Vision, Bionode, Carl Zeiss, Centricity Vision Inc, Ciliatech, CorNeat Vision, Custom Surgical, Dragonfleye Therapeutics Corp, Elios Vision, ElutiMed, Eye to Eye Telehealth Inc, eyeFlow Inc, EyeMed, EyeQ Technologies, EyeX Solutions, Exhaura Limited, Glaukos, Gore, Hexiris Pharma, Iantrek, iCare, Implandata, InjectSense, Iridex, iStar, Johnson & Johnson Vision, LayerBio, LIQID Medical, Long Bridge Medical Inc, Medicontur, MST Surgical, Myra Vision, New World Medical, Nova Eye, Noxelis, Ocular Instruments, Ocular Therapeutix, Oculus Surgical, OcuSciences, Omega Ophthalmics, Ophthalmic Therapeutic Innovations LLC, Peripherex, PolyActiva, PulseMedica, Qlaris Bio, Radiance Therapeutics Inc, Radius XR, Regeneron Pharmaceuticals Inc, Rheon Medical SA, Ripple Therapeutics, Sanoculis, Santen, SeonixBio, Shifamed LLC, Singapore Biodesign, Sight Sciences, Smartlens Inc, Stroma, Tavo BioTherapeutics Inc, TFS Health Science, Thea Pharma, ViaLase, Visci Ltd, Visus Therapeutics, Vizzario and Zilia Inc. Research grant/support from AbbVie, Alcon, Bionode LLC, CorNeat Vision, Elios Vision, Glaukos, Gore Medical, iCare, iStar, Johnson & Johnson Vision, Myra Vision, New World Medical and Santen.
In this interview, Dr Chang answers the following questions:
Dr David F Chang, MD, is a Summa Cum Laude graduate of Harvard College and Harvard Medical School. He completed his ophthalmology residency at the University of California, San Francisco where he achieved the rank of clinical professor in 1999. Dr Chang is past president of the American Society of Cataract and Refractive Surgery (ASCRS) and he served on their executive board for 15 years. He is a past chair of the American Academy of Ophthalmology (AAO) Cataract Preferred Practice Pattern Panel and the AAO Annual Meeting Program Committee. Dr Chang previously served as chief medical editor of EyeWorld and Cataract and Refractive Surgery Today. He is past chair of the ASCRS Foundation and received the 2019 AAO Humanitarian Service Award and the 2020 Aravind Venkataswamy Award. Dr Chang is co-founder and the advisory board chair of EyeSustain, a global consortium of more than 50 eye societies advancing sustainability in ophthalmology. Dr Chang has received the highest honours for an anterior segment surgeon from the following international organizations: AAO (Kelman Lecture), ASCRS (Binkhorst Medal and Kelman Innovator Award), European Society Of Cataract & Refractive Surgeons (Ridley Medal), Asia-Pacific Association of Cataract and Refractive Surgeons (Lim Medal), United Kingdom & Ireland Society of Cataract & Refractive Surgeons (Rayner Medal), Royal Australian and New Zealand College of Ophthalmologists (Gregg Medal), Asia-Pacific Academy of Ophthalmology (Jose Rizal International Medal), The Middle East African Council of Ophthalmology (El-Maghraby International Award), and the International Council of Ophthalmology (Tadeusz Krwawicz Gold Medal). Including these, he has delivered more than 50 named lectures. In a poll of American ophthalmologists, Dr Chang was voted #3 in Newsweek’s 2023 list of the top 100 ophthalmologists in the United States. He was ranked #2 in the 2024 ‘Power List’ of the 100 most influential ophthalmologists, as selected by The Ophthalmologist.
Dr David F Chang discloses: Consultancy fees from Alcon, Carl Zeiss, Centricity, EyeMed, Forsight Robotics, ForSight Vision 6, Iantrek, Jellisee, Johnson & Johnson Vision, Longbridge Medical, Orasis, Perfect Lens, RxSight, Surface and Sydnexis. Stock/shareholder (self-managed) Centricity, Forsight Robotics, ForSight Vision 6, Iantrek, Jellisee, Longbridge Medical, Orasis, Perfect Lens, RxSight, Surface and Sydnexis.
In this interview, Dr Loh answers the following questions:
Dr Jennifer Loh, MD, is a board-certified ophthalmologist practising in Miami, Florida, with a focus on cataract and refractive surgery and dry eye disease. Dr Loh is founder and medical director of her practice, Loh Ophthalmology Associates, which she started in 2016. Dr Loh also spends her time as a clinical and surgical attending for the Larkin Hospital Ophthalmology Residency programme. She is a graduate of Indiana University School of Medicine, where she completed both medical school and ophthalmology residency. On a personal note, Dr Loh enjoys skiing and travelling the world with her husband and 6-year-old son.
Dr Jennifer Loh discloses: Advisory board/panel fees from AbbVie, Alcon, Bausch and Lomb, Beaver Visitec International, Biotissue, Bruder Healthcare, Dompe, Eyenovia, Horizon Therapeutics, Johnson & Johnson Vision, Nordic Pharma, Novabay, Ocular Science, Orasis, Science Based Health, Sight Sciences, Sun Ophthalmics, Tarsus, Thea, Visus/Tenpoint Therapeutics and Zeiss. Consultancy fees from AbbVie, Alcon, Bausch and Lomb, Beaver Visitec International, Biotissue, Bruder Healthcare, C. Light Technologies, Dompe, Eyenovia, Horizon Therapeutics, Johnson & Johnson Vision, LensAR, Nordic Pharma, Ocular Science, Science Based Health, Sight Sciences, Sun Ophthalmics, Tarsus, Thea, Visus/Tenpoint Therapeutics and Zeiss. Grants/research support from Sight Sciences. Speakers’ bureau fees from AbbVie, Alcon, Orasis, Sight Sciences and Sun Ophthalmics.
After watching this activity, participants should be better able to:
In these interviews, three renowned ophthalmologists explore how to optimize phacoemulsification in cataract surgery and share best practices for enhancing surgical efficiency and outcomes. They discuss optimizing fluidics and ultrasound energy, ophthalmic viscosurgical device selection, and integrating technological advances in phacoemulsification into clinical practice.
This activity is jointly provided by USF Health and touchIME. Target Audience This activity has been designed to meet the educational needs of cataract and refractive surgeons and ophthalmologists involved in cataract surgery. USF Accreditation Disclosures USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships. Faculty Dr Ike K Ahmed discloses: Consultancy fees from AbbVie, Ace Vision Group Inc, Alcon, Aliph Medical, Apellis Pharmaceuticals, Aquea Health Inc, ArcScan, Avellino Lab USA Inc, Avisi Technologies Inc, Balance Ophthalmics, Bausch and Lomb, Beaver Visitec, Belkin Vision, Bionode, Carl Zeiss, Centricity Vision Inc, Ciliatech, CorNeat Vision, Custom Surgical, Dragonfleye Therapeutics Corp, Elios Vision, ElutiMed, Eye to Eye Telehealth Inc, eyeFlow Inc, EyeMed, EyeQ Technologies, EyeX Solutions, Exhaura Limited, Glaukos, Gore, Hexiris Pharma, Iantrek, iCare, Implandata, InjectSense, Iridex, iStar, Johnson & Johnson Vision, LayerBio, LIQID Medical, Long Bridge Medical Inc, Medicontur, MST Surgical, Myra Vision, New World Medical, Nova Eye, Noxelis, Ocular Instruments, Ocular Therapeutix, Oculus Surgical, OcuSciences, Omega Ophthalmics, Ophthalmic Therapeutic Innovations LLC, Peripherex, PolyActiva, PulseMedica, Qlaris Bio, Radiance Therapeutics Inc, Radius XR, Regeneron Pharmaceuticals Inc, Rheon Medical SA, Ripple Therapeutics, Sanoculis, Santen, SeonixBio, Shifamed LLC, Singapore Biodesign, Sight Sciences, Smartlens Inc, Stroma, Tavo BioTherapeutics Inc, TFS Health Science, Thea Pharma, ViaLase, Visci Ltd, Visus Therapeutics, Vizzario and Zilia Inc. Research grant/support from AbbVie, Alcon, Bionode LLC, CorNeat Vision, Elios Vision, Glaukos, Gore Medical, iCare, iStar, Johnson & Johnson Vision, Myra Vision, New World Medical and Santen. Dr David F Chang discloses: Consultancy fees from Alcon, Carl Zeiss, Centricity, EyeMed, Forsight Robotics, ForSight Vision 6, Iantrek, Jellisee, Johnson & Johnson Vision, Longbridge Medical, Orasis, Perfect Lens, RxSight, Surface and Sydnexis. Stock/shareholder (self-managed) Centricity, Forsight Robotics, ForSight Vision 6, Iantrek, Jellisee, Longbridge Medical, Orasis, Perfect Lens, RxSight, Surface and Sydnexis. Dr Jennifer Loh discloses: Advisory board/panel fees from AbbVie, Alcon, Bausch and Lomb, Beaver Visitec International, Biotissue, Bruder Healthcare, Dompe, Eyenovia, Horizon Therapeutics, Johnson & Johnson Vision, Nordic Pharma, Novabay, Ocular Science, Orasis, Science Based Health, Sight Sciences, Sun Ophthalmics, Tarsus, Thea, Visus/Tenpoint Therapeutics and Zeiss. Consultancy fees from AbbVie, Alcon, Bausch and Lomb, Beaver Visitec International, Biotissue, Bruder Healthcare, C. Light Technologies, Dompe, Eyenovia, Horizon Therapeutics, Johnson & Johnson Vision, LensAR, Nordic Pharma, Ocular Science, Science Based Health, Sight Sciences, Sun Ophthalmics, Tarsus, Thea, Visus/Tenpoint Therapeutics and Zeiss. Grants/research support from Sight Sciences. Speakers’ bureau fees from AbbVie, Alcon, Orasis, Sight Sciences and Sun Ophthalmics. Content reviewer Edgar M Espana MD has no relevant financial interests/relationships or affiliations in relation to this activity. Touch Medical Contributors Katrina Lester and Hannah Moir have no financial interests/relationships or affiliations in relation to this activity. USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity. Requirements for Successful Completion In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form. If you have questions regarding credit please contact cpdsupport@usf.edu Accreditations Physicians This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians. USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Advanced Practice Providers Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation. Date of original release: 10 September 2025. Date credits expire: 10 September 2026. If you have any questions regarding credit, please contact cpdsupport@usf.edu
View and download resources from this activity to support your learning and share with colleagues
The activity is jointly provided by USF Health and touchIME.
We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.
An independent medical education grant from Alcon Vision, LLC and Johnson & Johnson Surgical Vision, Inc.
The activity is jointly provided by USF Health and touchIME.
The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
USF
USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.
USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.
Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabeled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.
This content is intended for healthcare professionals in the USA, Latin America and Canada only.
Date of original release: 10 September 2025. Date credits expire: 10 September 2026.
AMA PRA Category 1 credits â„¢ expire: 10 September 2026
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.